Management ChangeMay 4, 2026, 07:03 AM
Pasithea Appoints Kartik Krishnan as Chief Medical Officer
AI Summary
Pasithea Therapeutics Corp. announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer, effective May 1, 2026. Dr. Krishnan will lead all clinical development and medical strategy for the company's lead drug candidate, PAS-004, a next-generation MEK inhibitor for neurofibromatosis type 1. His extensive experience, including the development of the FDA-approved MEK inhibitor cobimetinib, is expected to significantly advance the PAS-004 program.
Key Highlights
- Kartik Krishnan, M.D., Ph.D. appointed Chief Medical Officer (CMO).
- Appointment effective May 1, 2026.
- Dr. Krishnan will oversee clinical development of PAS-004 for NF1.
- He brings over 20 years of experience in clinical development.
- Previously CEO at OncoNano Medicines and CMO at Arcus Biosciences.
- Contributed to the FDA approval of MEK inhibitor cobimetinib.
Price Impact
More from KTTA